InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $16.340 4.02 (32.63%)+
Announcement
Release
7 May 2026 9:53AM
Price at Release
$12.320
Full Release
download
Summary
In Q1 2026, Neuren Pharmaceuticals Limited reported that DAYBUE® (trofinetide) achieved net sales of US$101 million, marking a 20% increase compared to Q1 2025. The newly launched DAYBUE STIX formulation was well-received, with significant prescriptions and high caregiver satisfaction. An expert panel recommended including DAYBUE in the standard care for Rett syndrome. Neuren's royalty income also rose by 23% to US$10.4 million. Their partner, Acadia Pharmaceuticals, maintained its sales guidance for DAYBUE, projecting US$460–490 million in net sales for the full year 2026.
Key Points
  • Q1 2026 DAYBUE® net sales reached US$101 million, a 20% increase from Q1 2025.
  • Positive initial reception of DAYBUE STIX with over 250 prescriptions and more than 80% caregiver satisfaction.
  • Delphi expert consensus recommended DAYBUE for Rett syndrome treatment.
  • Neuren earned Q1 2026 royalty income of US$10.4 million, a 23% increase from Q1 2025.
  • Acadia reaffirmed full-year 2026 DAYBUE net sales guidance of US$460–490 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.